Distribution of events among patients with loss of clinical benefit (N=146)
| Event | Total patients with loss of clinical benefit, N=146 | 1st TNFi patients, N=72 | 2nd, 3rd, and 4th TNFi patients, N=74 |
|---|---|---|---|
| CDAI>10, N (%) | 46 (31.5) | 10 (13.9) | 36 (48.6) |
| DMARD changes, N (%) | |||
| MTX started | 5 (3.4) | 1 (1.4) | 4 (5.4) |
| MTX increased | 34 (23.3) | 12 (16.7) | 22 (29.7) |
| Other DMARD started | 5 (3.4) | 2 (2.8) | 3 (4.1) |
| Other DMARD increased | 3 (2.1) | 1 (1.4) | 2 (2.7) |
| TNFi initiation/restart, N (%) | 10 (6.8) | 5 (6.9) | 5 (6.8) |
| Prednisone, N (%) | |||
| Started | 3 (2.1) | 1 (1.4) | 2 (2.7) |
| Increased | 11 (7.5) | 3 (4.2) | 8 (10.8) |
| Skin assessment >20, N (%) | 23 (15.8) | 7 (9.7) | 16 (21.6) |
In total, 179 patients had ongoing benefit by end of study.
CDAI, clinical disease activity index; DMARD, disease-modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitor.